Tepmetko Tab (tepotinib, Merck) is applying for reimbursement in Korea for the third time after failing to set a reimbursement standard at the Cancer Disease Deliberation Committee (CDDC) stage in March.

With no other treatment available for patients with MET-mutation positive metastatic non-small-cell lung cancer (NSCLC), the industry’s focus is on whether Tepmetko will succeed in receiving reimbursement approval this time.

According to industry sources on the 26th, MSD recently applied for reimbursement of Tepmetko to the Health Insurance Review and Assessment Service.

This is the third reimbursement application the company has filed for the drug. Tepmetko, which was